A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab.

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2005
This article has no abstract
Epistemonikos ID: efb7e489f9060639140ad43f20a67c513662c256
First added on: Apr 16, 2025